

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : LIN, et al.
U.S. Serial No.: 10/648,081
Filed : August 25, 2003
For : MODEL EPITHELIAL CELL CULTURES

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

January 08, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants hereby submit this Supplemental Information Disclosure Statement in accordance with their duty of disclosure under 37 C.F.R. §1.56. Applicants originally filed an Information Disclosure Statement for the above-identified application on December 2, 2003. Applicants would like to direct the Examiner's attention to the following references which are listed below as **Exhibits 1-6** and on Forms PTO/SB/08A and PTO/SB/08B (**Exhibit A**). Applicants' attorney's office may be contacted in the event that the Examiner would like a copy of all references filed with the December 2, 2003 Information Disclosure Statement.

The following references are attached:

1. PCT Notification of Transmittal of the International Search Report or the Declaration for Kinetana Group Inc., Int'l App'l No. PCT/CA03/01265, Filed on August 22, 2003, Dated December 15, 2003 [**Exhibit 1**]

Applicant : LIN, et al.
U.S. Serial No.: 10/648,081
Filed : August 25, 2003
Page : 2

2. PCT International Search Report for Kinetana Group Inc., Int'l App'l No. PCT/CA03/01265, Filed on August 22, 2003 **[Exhibit 2]**
3. European Patent Application No. 0684309A1, Swiderek et al., Filed November 29, 1995, Cell Culture Substrates and Methods of Use **[Exhibit 3]**
4. Beltman, et al. The Selective Protein Kinase C Inhibitor, Ro-31-8220, Inhibits Mitogen-activated Protein Kinase Phosphatase-1 (MKP-1) Expression, Induces c-Jun Expression, and Activates Jun N-terminal Kinase, The Journal of Biological Chemistry, 1996, 271(43):27018-27024 **[Exhibit 4]**
5. Rickard, et al. Activation of Protein Kinase C Augments Butyrate-induced Differentiation and Turnover in Human Colonic Epithelial Cells *in Vitro*. Carcinogenesis, 1999, 20(6):977-984 **[Exhibit 5]**
6. Schwartz, et al. Induction of the Differentiated Phenotype in Human Colon Cancer Cells is Associated with the Attenuation of Subcellular Tyrosine Phosphorylation, Pergamon, 0965-0407(95)02001-T **[Exhibit 6]**

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicant : LIN, et al.
U.S. Serial No.: 10/648,081
Filed : August 25, 2003
Page : 3

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is given to charge the amount of any such fee to Deposit Account No. 50-1891.


Respectfully submitted,

Albert Wai Kit Chan

I hereby certify that this paper is being deposited this date with the U.S. Postal Service with sufficient postage for first class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Albert Wai Kit Chan 1/8/04
Albert Wai-Kit Chan Date
Reg. No. 36,479

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicants
Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 357-8836
Fax: (718) 357-8615
E-mail: kitchenlaw@aol.com




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Swiderek, et al.

Date
Cons

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/648,081
Filing Date	August 25, 2003
First Named Inventor	LIN, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	784-A-US
Sheet 2 of 2	

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	Beltman, et al. The Selective Protein Kinase C Inhibitor, Ro-31-8220, Inhibits Mitogen-activated Protein Kinase Phosphatase-1 (MKP-1) Expression, Induces c-Jun Expression, and Activates Jun N-terminal Kinase, The Journal of Biological Chemistry, 1996, 271(43):27018-27024	
	5	Rickard, et al. Activation of Protein Kinase C Augments Butyrate-induced Differentiation and Turnover in Human Colonic Epithelial Cells in Vitro. Carcinogenesis, 1999, 20(6):977-984	
	6	Schwartz, et al. Induction of the Differentiated Phenotype in Human Colon Cancer Cells is Associated with the Attenuation of Subcellular Tyrosine Phosphorylation, Pergamon, 0965-0407(95)02001-T	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.